MedTrace Logo

An Advanced Echocardiographic Evaluation of Nebivolol

NCT01206439 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-02-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if Nebivolol has any effect on heart function determined by changes in echocardiographic data or exercise tolerance.

Conditions

Interventions

DRUG

nebivolol

nebivolol 5 or 10 mg oral, daily

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Jack Rubinstein

    lead OTHER

Principal Investigators

  • Jack Rubinstein, MD · University of Cincinnati

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01206439 on ClinicalTrials.gov